ECSP11011289A - Formulaciones galénicas de compuestos orgánicos - Google Patents

Formulaciones galénicas de compuestos orgánicos

Info

Publication number
ECSP11011289A
ECSP11011289A EC2011011289A ECSP11011289A ECSP11011289A EC SP11011289 A ECSP11011289 A EC SP11011289A EC 2011011289 A EC2011011289 A EC 2011011289A EC SP11011289 A ECSP11011289 A EC SP11011289A EC SP11011289 A ECSP11011289 A EC SP11011289A
Authority
EC
Ecuador
Prior art keywords
tablet
core
organic compounds
dosage form
coating
Prior art date
Application number
EC2011011289A
Other languages
English (en)
Inventor
Stefan Hirsch
Brethes Sabine Desset
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40770648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP11011289A publication Critical patent/ECSP11011289A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a una forma de dosificación unitaria sólida para su administración oral en la forma de una tableta que tiene un núcleo y un recubrimiento externo, en donde:- el núcleo de la tableta comprende una cantidad terapéuticamente efectiva de Alisquireno, o de una sal farmacéuticamente aceptable del mismo, y- el recubrimiento externo está en la forma de un recubrimiento de película, el cual tiene propiedades enmascaradoras de sabor y/o una funcionalidad de liberación controlada.De preferencia, la tableta de núcleo es parte de un sistema de múltiples partículas, en particular una minitableta. La forma de dosificación oral sólida es en particular adecuada para uso pediátrico.
EC2011011289A 2009-01-28 2011-08-26 Formulaciones galénicas de compuestos orgánicos ECSP11011289A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09151496 2009-01-28

Publications (1)

Publication Number Publication Date
ECSP11011289A true ECSP11011289A (es) 2011-09-30

Family

ID=40770648

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011289A ECSP11011289A (es) 2009-01-28 2011-08-26 Formulaciones galénicas de compuestos orgánicos

Country Status (28)

Country Link
US (1) US20110287100A1 (es)
EP (1) EP2391345B1 (es)
JP (1) JP2012516299A (es)
KR (1) KR20110117199A (es)
CN (1) CN102300558A (es)
AR (1) AR075179A1 (es)
AU (1) AU2010209787B2 (es)
BR (1) BRPI1007452A2 (es)
CA (1) CA2749531A1 (es)
CL (1) CL2011001817A1 (es)
CO (1) CO6400184A2 (es)
EC (1) ECSP11011289A (es)
ES (1) ES2525648T3 (es)
HK (1) HK1161125A1 (es)
IL (1) IL213918A0 (es)
MA (1) MA33060B1 (es)
MX (1) MX2011007779A (es)
MY (1) MY153852A (es)
NZ (1) NZ593622A (es)
PE (1) PE20110943A1 (es)
PL (1) PL2391345T3 (es)
PT (1) PT2391345E (es)
RU (1) RU2535090C2 (es)
SG (1) SG172226A1 (es)
TN (1) TN2011000307A1 (es)
TW (1) TWI468191B (es)
WO (1) WO2010086312A1 (es)
ZA (1) ZA201104489B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5822758B2 (ja) * 2011-03-02 2015-11-24 第一三共ヘルスケア株式会社 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2596802A1 (en) * 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
WO2017134600A1 (en) * 2016-02-03 2017-08-10 Novartis Ag New use of a combination of sacubitril and valsartan
JP7461295B2 (ja) 2018-08-10 2024-04-03 キッセイ薬品工業株式会社 スクロオキシ水酸化鉄含有顆粒及び医薬組成物
CN113490486A (zh) 2019-02-22 2021-10-08 康特伦英国斯温顿捷迪斯有限公司 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣
WO2020169991A1 (en) * 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Preserving functionally-coated api particles produced by solventless mixing processes in aqueous suspension
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
WO2005105054A1 (en) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Dosage form having polymorphic stability
US20080085914A1 (en) * 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
ES2364538T3 (es) * 2007-09-28 2011-09-06 Novartis Ag Combinación farmacéutica de alisquireno y valsartán.

Also Published As

Publication number Publication date
MY153852A (en) 2015-03-31
TN2011000307A1 (en) 2012-12-17
ZA201104489B (en) 2012-02-29
TWI468191B (zh) 2015-01-11
CL2011001817A1 (es) 2012-01-13
TW201038300A (en) 2010-11-01
ES2525648T3 (es) 2014-12-26
HK1161125A1 (en) 2012-08-24
CO6400184A2 (es) 2012-03-15
RU2535090C2 (ru) 2014-12-10
PT2391345E (pt) 2014-12-03
JP2012516299A (ja) 2012-07-19
WO2010086312A1 (en) 2010-08-05
KR20110117199A (ko) 2011-10-26
AU2010209787B2 (en) 2013-06-06
BRPI1007452A2 (pt) 2016-02-16
EP2391345A1 (en) 2011-12-07
NZ593622A (en) 2013-12-20
RU2011135417A (ru) 2013-03-10
AR075179A1 (es) 2011-03-16
CN102300558A (zh) 2011-12-28
SG172226A1 (en) 2011-07-28
IL213918A0 (en) 2011-07-31
EP2391345B1 (en) 2014-09-03
CA2749531A1 (en) 2010-08-05
US20110287100A1 (en) 2011-11-24
MX2011007779A (es) 2011-08-12
PL2391345T3 (pl) 2015-03-31
PE20110943A1 (es) 2012-01-22
AU2010209787A1 (en) 2011-07-14
MA33060B1 (fr) 2012-02-01

Similar Documents

Publication Publication Date Title
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
SMT201500317B (it) Forma di dosaggio farmaceutica per la somministrazione orale di un inibitore della famiglia di bcl-2
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201600093A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
JP2014111603A5 (es)
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
BRPI0810115A2 (pt) Métodos para administrar um medicamento a um paciente mecanicamente ventilado e para coordenar administração de um fluxo de ás e administração de um medicamento a um paciente mecanismo ventilado e sistema para administrar um medicamento em forma de aerosol a um paciente ventilado.
LTPA2019508I1 (lt) Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
TN2010000135A1 (en) Galenical formulations of organic compounds
CL2013000895A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de imidazo[4,5-c]-quinolina, inhibidor de pik3/mtor, un compuesto alosterico inhibidor de mtor y opcionalmente un vehiculo farmaceuticamente aceptable; composicion farmaceutica; metodo para mejorar la eficacia del tratamiento; y su uso en una enfermedad proliferativa.
PT2131823E (pt) Carapuço que pode ser apertado em torno da cabeça, peça de vestuário para ser usada na parte superior do corpo comportando um tal carapuço
CL2008000424A1 (es) Composicion farmaceutica que comprende oglemilast o una sal farmaceuticamente aceptable de este compuesto; formas amorfas de dicho compuesto; y su uso para tratar inflamacion, afecciones respiratorias o alergicas.
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada